NVS

Summary

Sell NVS into strength at current levels. Our analysis is to cut longs, avoid dip buying, and stay flat to light tactical short only on a bounce into overhead supply. Size very lightly given elevated volatility. Key risks are a settled close back above overhead supply with momentum stabilizing, or M&A and target clarity sparking a squeeze toward the prior upside level over a short term horizon.

The case

1. Fundamental repricing, not a dip: multiple late stage failures in a week weighed on the outlook, including a cardiovascular outcomes failure in a large trial and a missed endpoint undermining the $12 bet, described as the worst day on record down to -12%. Our analysis sees this questioning M&A strategy and long term growth targets reported in news coverage. 2. Technical breakdown with overhead supply: NVS trades below key moving averages with weak momentum and heavy unfinished volume, with overhead supply capping bounces. Leverage adds pressure with net debt up 63% year over year, leaving negative working capital after debt funded business purchases. 3. Hedging, not accumulation: implied volatility at 36.1% signals a fear regime with hedging rather than accumulation, alongside contagion weakness with IONS at -13.1% and AMGN at -8%. 4. Long term value versus short term timing: bull math citing 30% return on equity, 75% margin, 2.96% yield and the $3.2B deal is longer term but mistimed for short term alpha. Our analysis avoids chasing fresh shorts into capitulation and elevated volatility; Sell means reduce risk to neutral and light, not an aggressive levered short.

What would weaken it

• Close back above supply with RSI turn and histogram trough
• M&A or target clarity squeeze to prior upside
• Value bid on yield and margin stabilizes price